patient-related-outcomes-bg patient-related-outcomes-bg

To decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

PATIENT-REPORTED OUTCOME MEASURES WITH COSELA IN A RETROSPECTIVE POOLED ANALYSIS

POOLED ANALYSIS OF EXPLORATORY ENDPOINTS ACROSS THREE STUDIES: COSELA® (trilaciclib) Proactively Given Prior to Etoposide/Carboplatin/Atezolizumab (E/P/A) or E/P in 1st-Line ES-SCLC Treatment and Prior to Topotecan in 2nd- or 3rd-Line

See Study Design 
  • Patient-reported outcomes (PRO) data were descriptive and exploratory study endpoints in the three clinical studies to measure COSELA's effects on health-related quality of life (HRQoL). For each study, PRO completion rates were >80% in both the COSELA and placebo groups. Outcome measures were not validated in the study population; therefore, no conclusions can be drawn
  • Caution should be taken when interpreting data pooled analysis, because differences in the patient population and chemotherapy backbones exist across the three individual studies

median time to confirmed deterioration (ttcd) in patient-reported outcomes1

COSELA PRIOR TOCHEMOTHERAPY BETTER PLACEBO PRIOR TOCHEMOTHERAPYBETTER HAZARD RATIO (95% CI) 0.56 (0.37-0.85) 0.54 (0.35-0.84) 1 Fatigue Anemia trial outcome index 0.8 0.6 0.4 1.4 1.2 0.2 DOMAIN 0.47 (0.30-0.73) FACT-Anemia total 0.62 (0.40-0.97) 0.45 (0.29-0.71) Physical wellbeing Functional wellbeing EVENTS (N) COSELA TTCD (MONTHS) PLACEBO COSELA PLACEBO 39 33 31 32 31 61 55 58 51 55 7.03 7.20 NYR NYR 7.62 2.33 3.78 3.48 5.16 3.78 1.6 DOMAIN EVENTS (N) COSELA TTCD (MONTHS) PLACEBO COSELA PLACEBO 39 33 31 32 31 61 55 58 51 55 7.03 7.20 NYR NYR 7.62 2.33 3.78 3.48 5.16 3.78 COSELA PRIOR TOCHEMOTHERAPY BETTER PLACEBO PRIOR TOCHEMOTHERAPYBETTER HAZARD RATIO (95% CI) 1 0.8 0.6 0.4 1.4 1.2 0.2 1.6 Fatigue Anemia trial outcome index FACT-Anemia total Physical wellbeing Functional wellbeing Fatigue Anemia trial outcome index FACT-Anemia total Physical wellbeing Functional wellbeing 0.56 (0.37-0.85) 0.54 (0.35-0.84) 0.47 (0.30-0.73) 0.62 (0.40-0.97) 0.45 (0.29-0.71)

Pooled data from all three studies were evaluated to provide more precise estimates of trilaciclib treatment effects for low frequency RBC-related events and to assess consistency of treatment effect by trilaciclib across relevant subgroups.

Chemotherapy Regimen Arm = Placebo + E/P/A or E/P or Topotecan.

NYR=not yet reached

  • Subscales and measures of the FACT-Anemia (Functional Assessment of Cancer Therapy-Anemia or FACT- An) questionnaire, considered most relevant to measure the impact of chemotherapy on patient HRQoL, were selected a priori for the pooled analysis. At baseline, across all of the studies, mean scores for these domains were similar between the COSELA groups, with the placebo groups having slightly higher values
  • Time to confirmed deterioration (TTCD), or worsening, was defined as a decrease from baseline by a clinically meaningful threshold for 2 consecutive visits: ≤3 points for physical wellbeing, functional wellbeing, and fatigue; ≤6 points for anemia trial outcome index points: ≤7 points for FACT-Anemia (Functional Assessment of Cancer Therapy-Anemia or FACT-An) scores. Meaningful change thresholds were derived from published literature
  • TTCD analyses may be influenced by definition of worsening, intercurrent events (ie, toxicity, death, etc), and PRO assessment frequency2
HEAR FROM A PEER

JASON PORTER, MD, SHARES THE IMPACT CHEMOTHERAPY-INDUCED MYELOSUPPRESSION CAN HAVE ON THE DAILY LIFE OF PATIENTS

Watch Video >
Jason Porter quote "the patient experience really is affect by low blood cell counts" Jason Porter quote "the patient experience really is affect by low blood cell counts"
Search icon

REVIEW
CLINICAL EFFICACY

See Data >
Shield icon

SAFETY

Review Data >
Resources icon

RESOURCES FOR Healthcare Professionals

See Access & Support >